CN Patent

CN1747736A — 包含芳化酶抑制剂、孕激素和雌激素组合的组合物及其治疗子宫内膜异位症的用途

Assigned to AstraZeneca AB · Expires 2006-03-15 · 20y expired

What this patent protects

本发明涉及一种使用芳化酶抑制剂、孕激素和雌激素的组合治疗子宫内膜异位症的方法。本发明还涉及含有所述组合的药物制剂。

USPTO Abstract

本发明涉及一种使用芳化酶抑制剂、孕激素和雌激素的组合治疗子宫内膜异位症的方法。本发明还涉及含有所述组合的药物制剂。

Drugs covered by this patent

elagolix-sodium (ELAGOLIX SODIUM)

Patent Metadata

Patent number: CN1747736A
Jurisdiction: CN
Classification: —
Expires: 2006-03-15
Drug substance claim: No
Drug product claim: No
Assignee: AstraZeneca AB
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.